Compare Vistra Corp (VST) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vistra Corp vs Viatris Inc — how do they compare? Vistra Corp trades at $151.11 (market cap $50.11B), while Viatris Inc trades at $16.45 (market cap $19.09B). The key difference: Vistra Corp is far larger — about 2.6× Viatris Inc's market cap, and Viatris Inc pays the higher dividend (2.89%). Which is the better fit depends on your goals.
| VST | VTRS | |
|---|---|---|
Market Cap | $50.11B | $19.09B |
Sector | Technology | Health |
52-Week High | $217.92 | $17.86 |
52-Week Low | $134.71 | $9.49 |
Enterprise Value | $72.05B | $31.21B |
Dividend Yield | 0.62% | 2.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Vistra Corp. (VST) trades at $151.72, up 1.62% today, with a bullish technical signal and strong analyst support. The stock shows mixed quarterly earnings but projects significant revenue and net income growth into 2026. Recent news highlights CEO and institutional buying, long-term power agreements with tech giants, and a consensus price target of $228.40, suggesting substantial upside potential from current levels.
The outlook is positive, driven by robust power demand, strategic partnerships, and a diversified generation fleet. Key risks include regulatory uncertainty and earnings volatility. With 91% of analysts rating it a buy and insider confidence, VST presents a compelling opportunity for growth-oriented investors, though market fluctuations and execution risks warrant caution.
Viatris (VTRS) trades at $16.61, down 1.6% over the past 24 hours. The stock exhibits a mixed technical picture with a bullish overall signal but bearish moving averages. Fundamentally, the company reported a net loss of $3.51 billion in 2025 despite revenue of $14.30 billion, though recent quarters have shown earnings beats. Positive cash flow generation and a dividend payment highlight financial stability, while analyst sentiment is mixed with a majority hold rating.
The outlook for VTRS hinges on its ability to return to profitability and sustain operational improvements. Investment opportunities include strong cash flow, deleveraging progress, and pipeline developments, but risks involve persistent net losses, competitive pressures, and potential regulatory impacts from proposed generic drug tariffs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Vistra Corp
Vistra is a leading integrated retail electricity and power generation company that serves as a critical infrastructure provider for the digital economy. It operates a diversified portfolio of zero-carbon nuclear and renewable assets alongside a massive, flexible natural gas fleet, positioning it as an indispensable partner for energy-intensive AI data centers and industrial electrification.
Read more on VST →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
